Skip to main content
OpenTrials
Completed

NCT Number: NCT02746159

Lutonix® Global AV Registry Investigating Lutonix Drug Coated Balloon for Treatment of Native and Synthetic AV Fistulae

The purpose of this Registry is to enroll patients presenting with clinical and hemodynamic abnormalities in native or synthetic (grafts) arteriovenous (AV) fistulae located in the arm. Subjects will be treated with the Lutonix DCB carrying the CE Mark per current IFU and followed clinically for a minimum of 12 months.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This post market registry is intended to demonstrate safety and assess the clinical use and outcomes of the Lutonix DCB in a heterogeneous patient population with dysfunctional native or synthetic AV fistulae in real world clinical practice.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or non-pregnant, non-breastfeeding female ≥18 years of age;
  • Patient is willing to provide informed consent, and is willing to comply with the protocol-required follow up visits;
  • Native or synthetic (grafts) arteriovenous fistula located in the arm, including central veins, presenting with any clinical, physiological or hemodynamic abnormalities warranting angiographic imaging as defined in the K/DOQI guidelines; and
  • Lesion(s) can be treated with available Lutonix DCB device size matrix per current IFU.

Exclusion criteria

Patients will be excluded if ANY of the following conditions apply:

  • Patient is currently participating in an investigational drug or device study which has not yet reached its primary endpoint or was previously enrolled into this registry (i.e. Lutonix Global AV registry).
  • Patient has a non-controllable allergy to contrast; or
  • Patient has another medical condition that, which in the opinion of the Investigator, may confound the data interpretation of is associated with a life expectancy insufficient to allow for completion of patient registry procedure and follow up.

Treatment and study plan

Lutonix 035 Drug Coated Balloon PTA Catheter, Model 9004

Device

Primary outcomes

  1. Proportion of subjects with freedom from any serious adverse event(s) involving the AV access circuit

    Time frame: 30 days.

    Primary safety events include any serious adverse event(s) involving the AV access circuit

  2. Proportion of subjects with target lesion primary patency

    Time frame: 6 Months

    Defined as the interval following index procedure until clinically-driven reintervention of the target lesion or access thrombosis, through 6 months.

    Clinically-driven reintervention is defined as a lesion that has ≥50% stenosis and at least one clinical, physiological or hemodynamic abnormality attributable to the stenosis defined in the K/DOQI guidelines.

Secondary outcomes

  1. Proportion of subjects with access circuit primary patency at 3, 6, and 12 months

    Time frame: 12 months

    Interval following intervention until the next access circuit thrombosis or repeated intervention. Ends with treatment of a lesion anywhere within the access circuit.

  2. Proportion of Subjects withTarget Lesion Primary Patency (TLPP)

    Time frame: 12 months

    Target Lesion Primary Patency (TLPP) is defined as the interval following index procedure intervention until clinically driven reintervention of the target lesion or access thrombosis.

  3. Proportion of Subjects with Abandonment of permanent access in the index extremity

    Time frame: 12 months

    The arteriovenous fistula / access circuit is considered abandoned when it is no longer being used for dialysis because the access was not functioning.

  4. Proportion of Subjects with Device Success

    Time frame: 12 Months

    Successful delivery to the target lesion, deployment, and retrieval at index procedure. If a device is inserted into the subject but not used due to user error (e.g. inappropriate balloon length or transit time too long), this device will not be included in the device success assessment.

  5. Proportion of Subjects with Procedural Success

    Time frame: 12 Months

    At least one indicator of hemodynamic success (e.g., physical examination with restoration of a thrill, direct measurement of flow) in the absence of peri-procedural (index procedure and through hospital stay) Serious Adverse Device Effects (SADEs).

  6. Proportion of Subjects with Clinical Success

    Time frame: 12 Months

    The resumption of dialysis for at least one session after the index procedure.

  7. Rate of device and procedure related adverse events

    Time frame: 12 months

    Freedom from device-related or procedure-related serious adverse events

Sponsors and collaborators

Lead sponsor

C. R. Bard

Industry

Registry information

Official study title

A Prospective, Multicenter, Single Arm Real-World Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon PTA Catheter for Treatment of Dysfunctional Native and Synthetic AV Fistulae

Acronym: AVR

Important dates

Study start
2016
Primary completion
2018
Study completion
2019
First posted
Apr 21, 2016
Registry last updated
Feb 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.